Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה מיובשת בהקפאה להזרקה - moroctocog alfa 250 iu/vial - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

Israel - hebraisk - Ministry of Health

medison pharma ltd - eflornithine as hydrochloride monohydrate - קרם - eflornithine as hydrochloride monohydrate 11.5 %w/w - eflornithine - eflornithine - vaniqa is indicated for the reduction of unwanted facial hair in women.

Israel - hebraisk - Ministry of Health

cts ltd - ciprofloxacin as hydrochloride; fluocinolone acetonide - טיפות אוזניים - ciprofloxacin as hydrochloride 3 mg / 1 ml; fluocinolone acetonide 0.25 mg / 1 ml - ciprofloxacin - ciprofloxacin - local treatment of acute diffuse otitis externa of bacterial origin without tympanic membrane perforation in adults and children above the age of 7 years.

Israel - hebraisk - Ministry of Health

zoetis israel holding b.v., israel - moxidectin; praziquantel - ג'ל - moxidectin 1.95 %w/w; praziquantel 12.17 %w/w - equest pramox veterinary is indicated for treatment of mixed cestodes and nematodes or arthropods infections, caused by moxidectin and praziquantel sensitive strains of : large strongyles, small strongyles (adults and intraluminal larval stages), ascarids and other species, tapeworm (adults). the egg reappearance period of small strongyles is 90 days. the product is effective against (developing) intramucosal l4 stages of small strongyles. at 8 weeks after treatment, early (hypobiotic) el3 stages of small strongyles are eliminated.

Israel - hebraisk - Ministry of Health

taro international ltd, israel - etoricoxib - טבליות מצופות פילם - etoricoxib 120 mg - etoricoxib

Israel - hebraisk - Ministry of Health

taro international ltd, israel - etoricoxib - טבליות מצופות פילם - etoricoxib 30 mg - etoricoxib

Israel - hebraisk - Ministry of Health

taro international ltd, israel - etoricoxib - טבליות מצופות פילם - etoricoxib 60 mg - etoricoxib